Patents by Inventor Shunpei Ishikawa

Shunpei Ishikawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10851079
    Abstract: The purpose of the present invention is to provide a compound having excellent antibacterial activity against mycobacterium tuberculosis, multidrug-resistant tuberculosis bacteria, and/or non-tuberculous acid-fast bacteria. A compound represented by formula [I]: (in the formula, each symbol is as described in the attached specification), or a salt thereof can be used to diagnose, prevent, and/or treat tuberculosis.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: December 1, 2020
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Yoshikazu Kawano, Hiroshi Shimizu, Shunpei Ishikawa, Isao Takemura, Norimitsu Hariguchi, Miki Matsuba, Makoto Matsumoto
  • Patent number: 10696743
    Abstract: Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes a DSG3 protein. Pharmaceutical compositions, cell growth inhibitors, and anticancer agents containing a DSG3-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in DSG3-expressing cells and methods of suppressing proliferation of DSG3-expressing cells by contacting the DSG3-expressing cells with DSG3-binding antibodies are also disclosed.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: June 30, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hiroyuki Aburatani, Shunpei Ishikawa, Hirotaka Ito, Kiyotaka Nakano, Shigeto Kawai
  • Patent number: 10464926
    Abstract: It is an object of the present invention to provide a compound having an excellent antibacterial activity against tuberculosis bacteria, multidrug-resistant tuberculosis bacteria and/or non-tuberculous mycobacteria. Disclosed is a compound of the general formula (1): wherein each symbol is defined as described in the attached specification, or a salt thereof.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: November 5, 2019
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi Shimizu, Yoshikazu Kawano, Shunpei Ishikawa, Yukitaka Uematsu, Toshio Shinohara, Motohiro Itotani, Yoshikazu Haraguchi, Isao Takemura, Atsunori Kaneshige, Yuya Nakai, Norimitsu Hariguchi, Yohei Hayashi, Makoto Matsumoto
  • Publication number: 20190040039
    Abstract: The purpose of the present invention is to provide a compound having excellent antibacterial activity against mycobacterium tuberculosis, multidrug-resistant tuberculosis bacteria, and/or non-tuberculous acid-fast bacteria. A compound represented by formula [I]: (in the formula, each symbol is as described in the attached specification), or a salt thereof can be used to diagnose, prevent, and/or treat tuberculosis.
    Type: Application
    Filed: February 27, 2017
    Publication date: February 7, 2019
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Yoshikazu KAWANO, Hiroshi SHIMIZU, Shunpei ISHIKAWA, Isso TAKEMURA, Norimitsu HARIGUCHI, Miki MATSUBA, Makoto MATSUMOTO
  • Publication number: 20180312488
    Abstract: It is an object of the present invention to provide a compound having an excellent antibacterial activity against tuberculosis bacteria, multidrug-resistant tuberculosis bacteria and/or non-tuberculous mycobacteria. Disclosed is a compound of the general formula (1): wherein each symbol is defined as described in the attached specification, or a salt thereof.
    Type: Application
    Filed: July 9, 2018
    Publication date: November 1, 2018
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi SHIMIZU, Yoshikazu KAWANO, Shunpei ISHIKAWA, Yukitaka UEMATSU, Toshio SHINOHARA, Motohiro ITOTANI, Yoshikazu HARAGUCHI, Isao TAKEMURA, Atsunori KANESHIGE, Yuya NAKAI, Norimitsu HARIGUCHI, Yohei HAYASHI, Makoto MATSUMOTO
  • Patent number: 10053446
    Abstract: It is an object of the present invention to provide a compound having an excellent antibacterial activity against tuberculosis bacteria, multidrug-resistant tuberculosis bacteria and/or non-tuberculous mycobacteria. Disclosed is a compound of the general formula (1): wherein each symbol is defined as described in the attached specification, or a salt thereof.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: August 21, 2018
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi Shimizu, Yoshikazu Kawano, Shunpei Ishikawa, Yukitaka Uematsu, Toshio Shinohara, Motohiro Itotani, Yoshikazu Haraguchi, Isao Takemura, Atsunori Kaneshige, Yuya Nakai, Norimitsu Hariguchi, Yohei Hayashi, Makoto Matsumoto
  • Publication number: 20170253576
    Abstract: It is an object of the present invention to provide a compound having an excellent antibacterial activity against tuberculosis bacteria, multidrug-resistant tuberculosis bacteria and/or non-tuberculous mycobacteria. Disclosed is a compound of the general formula (1): wherein each symbol is defined as described in the attached specification, or a salt thereof.
    Type: Application
    Filed: August 28, 2015
    Publication date: September 7, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi SHIMIZU, Yoshikazu KAWANO, Shunpei ISHIKAWA, Yukitaka UEMATSU, Toshio SHINOHARA, Motohiro ITOTANI, Yoshikazu HARAGUCHI, Isao TAKEMURA, Atsunori KANESHIGE, Yuya NAKAI, Norimitsu HARIGUCHI, Yohei HAYASHI, Makoto MATSUMOTO
  • Publication number: 20170152314
    Abstract: Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes a DSG3 protein. Pharmaceutical compositions, cell growth inhibitors, and anticancer agents containing a DSG3-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in DSG3-expressing cells and methods of suppressing proliferation of DSG3-expressing cells by contacting the DSG3-expressing cells with DSG3-binding antibodies are also disclosed.
    Type: Application
    Filed: February 10, 2017
    Publication date: June 1, 2017
    Inventors: Hiroyuki ABURATANI, Shunpei Ishikawa, Hirotaka Ito, Kiyotaka Nakano, Shigeto Kawai
  • Patent number: 9139647
    Abstract: The present invention relates to an antibody binding to a TM4SF20 protein and the diagnosis and treatment of cancer using the antibody. Specifically, the present invention provides an anti-TM4SF20 antibody and a pharmaceutical composition (e.g., an anticancer agent and a diagnostic drug for cancer) comprising the antibody as an active ingredient.
    Type: Grant
    Filed: December 25, 2009
    Date of Patent: September 22, 2015
    Assignees: FORERUNNER PHARMA RESEARCH CO., LTD., THE UNIVERSITY OF TOKYO
    Inventors: Hiroyuki Aburatani, Shunpei Ishikawa, Shigeto Kawai
  • Patent number: 9079957
    Abstract: [Problem to be Solved] An object of the present invention is to provide novel means for the treatment and diagnosis of cancer. [Solution] The present inventors have obtained a monoclonal antibody against TMPRSS11E and found that this antibody binds to a native form of TMPRSS11E, and TMPRSS11E is highly expressed on the cell membranes of cancer cell lines in flow cytometry. This antibody exhibits antibody-dependent cell-mediated cytotoxicity activity (ADCC activity) and antitumor effect based on internalization activity and is promising as a therapeutic target. Moreover, this antibody has neutralization activity against protease activity and is also expected to have effect brought about by the inhibition of TMPRSS11E functions.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: July 14, 2015
    Assignees: THE UNIVERSITY OF TOKYO, FORERUNNER PHARMA RESEARCH CO., LTD.
    Inventors: Hiroyuki Aburatani, Shunpei Ishikawa, Kiyotaka Nakano
  • Publication number: 20120128678
    Abstract: [Problem to be Solved] An object of the present invention is to provide novel means for the treatment and diagnosis of cancer. [Solution] The present inventors have obtained a monoclonal antibody against TMPRSS11E and found that this antibody binds to a native form of TMPRSS11E, and TMPRSS11E is highly expressed on the cell membranes of cancer cell lines in flow cytometry. This antibody exhibits antibody-dependent cell-mediated cytotoxicity activity (ADCC activity) and antitumor effect based on internalization activity and is promising as a therapeutic target. Moreover, this antibody has neutralization activity against protease activity and is also expected to have effect brought about by the inhibition of TMPRSS11E functions.
    Type: Application
    Filed: April 15, 2010
    Publication date: May 24, 2012
    Applicants: Forerunner Pharma Research Co., Ltd., The University of Tokyo
    Inventors: Hiroyuki Aburatani, Shunpei Ishikawa, Kiyataka Nakano
  • Publication number: 20120004117
    Abstract: The present invention relates to an antibody binding to a TM4SF20 protein and the diagnosis and treatment of cancer using the antibody. Specifically, the present invention provides an anti-TM4SF20 antibody and a pharmaceutical composition (e.g., an anticancer agent and a diagnostic drug for cancer) comprising the antibody as an active ingredient.
    Type: Application
    Filed: December 25, 2009
    Publication date: January 5, 2012
    Applicants: Forerunner Pharma Research Co., Ltd., The University of Tokyo
    Inventors: Hiroyuki Aburatani, Shunpei Ishikawa, Shigeto Kawai
  • Publication number: 20100092457
    Abstract: Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes a DSG3 protein. Pharmaceutical compositions, cell growth inhibitors, and anticancer agents containing a DSG3-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in DSG3-expressing cells and methods of suppressing proliferation of DSG3-expressing cells by contacting the DSG3-expressing cells with DSG3-binding antibodies are also disclosed.
    Type: Application
    Filed: August 14, 2007
    Publication date: April 15, 2010
    Applicants: Forerunner Pharma Research Co., Ltd., The University of Tokyo
    Inventors: Hiroyuki Aburatani, Shunpei Ishikawa, Hirotaka Ito, Kiyotaka Nakano, Shigeto Kawai
  • Publication number: 20060135750
    Abstract: With the object of providing a novel protein expression of which is specifically elevated in abnormal cells or abnormal tissue, and also providing a diagnostic method and diagnostic kit for diseases involving elevated expression of a gene encoding that protein, along with a screening method and screening kit for substances for preventing and treating diseases involving elevated expression of a gene encoding that protein, (a) a protein comprising the amino acid sequence represented by Seq. ID No. 2 or (b) a protein comprising the amino acid sequence represented by Seq. ID No.
    Type: Application
    Filed: June 24, 2005
    Publication date: June 22, 2006
    Applicants: TOUDAI TLO, Ltd., CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Hiroyuki Aburatani, Hirotaka Ito, Shunpei Ishikawa, Shinichi Fukumoto